AU2013334707B2 - ETP derivatives - Google Patents

ETP derivatives Download PDF

Info

Publication number
AU2013334707B2
AU2013334707B2 AU2013334707A AU2013334707A AU2013334707B2 AU 2013334707 B2 AU2013334707 B2 AU 2013334707B2 AU 2013334707 A AU2013334707 A AU 2013334707A AU 2013334707 A AU2013334707 A AU 2013334707A AU 2013334707 B2 AU2013334707 B2 AU 2013334707B2
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
heterocycloalkyl
cycloalkyl
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013334707A
Other languages
English (en)
Other versions
AU2013334707A1 (en
Inventor
Marcus Baumann
David Horne
Richard Jove
Claudia KOWOLIK
Sangkil Nam
Larry Eugene OVERMAN
Jun Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of AU2013334707A1 publication Critical patent/AU2013334707A1/en
Application granted granted Critical
Publication of AU2013334707B2 publication Critical patent/AU2013334707B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013334707A 2012-10-22 2013-10-22 ETP derivatives Active AU2013334707B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261716803P 2012-10-22 2012-10-22
US61/716,803 2012-10-22
US201361799160P 2013-03-15 2013-03-15
US61/799,160 2013-03-15
PCT/US2013/066252 WO2014066435A1 (en) 2012-10-22 2013-10-22 Etp derivatives

Publications (2)

Publication Number Publication Date
AU2013334707A1 AU2013334707A1 (en) 2015-05-07
AU2013334707B2 true AU2013334707B2 (en) 2018-02-22

Family

ID=50545193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013334707A Active AU2013334707B2 (en) 2012-10-22 2013-10-22 ETP derivatives

Country Status (7)

Country Link
US (3) US9527868B2 (enExample)
EP (1) EP2909214B1 (enExample)
JP (3) JP6465803B2 (enExample)
CN (2) CN108440571B (enExample)
AU (1) AU2013334707B2 (enExample)
CA (1) CA2900335C (enExample)
WO (1) WO2014066435A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
NZ720004A (en) 2013-11-18 2020-03-27 Forma Therapeutics Inc Tetrahydroquinoline compositions as bet bromodomain inhibitors
ES2768678T3 (es) 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
KR20170016498A (ko) 2014-06-17 2017-02-13 버텍스 파마슈티칼스 인코포레이티드 Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
AU2016276172B2 (en) * 2015-06-08 2019-07-11 The Regents Of The University Of California Use of H3K9me3 modulation for enhancing cognitive function
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
JP7088912B2 (ja) * 2016-09-15 2022-06-21 シティ・オブ・ホープ ジチオｅｔｐ誘導体
KR102637541B1 (ko) * 2017-05-17 2024-02-15 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
US11766442B2 (en) 2017-06-16 2023-09-26 City Of Hope T-cell lymphoma treatments
PL3538645T3 (pl) 2017-06-20 2021-11-08 Institut Curie Komórki odpornościowe z defektem suv39h1
EP3641739A1 (en) 2017-06-20 2020-04-29 Institut Curie Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
HUE066783T2 (hu) 2018-04-18 2024-09-28 Constellation Pharmaceuticals Inc Metil módosító enzimek modulátorai, ezek készítményei és alkalmazásuk
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN111205308B (zh) * 2020-01-19 2022-03-15 中国科学院海洋研究所 一种硫代二酮哌嗪类化合物及其制备方法和应用
EP4188395A1 (en) 2020-07-30 2023-06-07 Institut Curie Immune cells defective for socs1
EP4456910A1 (en) 2021-12-28 2024-11-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
CN114751919B (zh) * 2022-03-18 2023-05-23 华南理工大学 一种环丁烷稠合螺环吲哚啉类化合物及其制备方法和应用
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024137659A1 (en) * 2022-12-20 2024-06-27 Cedars-Sinai Medical Center Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1409085A (en) * 1971-11-22 1975-10-08 Licentia Gmbh Method and apparatus for data transmission
WO1997048706A1 (en) * 1996-06-18 1997-12-24 Warner-Lambert Company Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors
WO2008112014A1 (en) * 2006-10-05 2008-09-18 Mayo Foundation For Medical Education And Research Methods and compositions for treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1A (en) * 1836-07-13 John Ruggles Locomotive steam-engine for rail and other roads
AR206504A1 (es) * 1972-11-03 1976-07-30 Lepetit Spa Un procedimiento para preparar 6,7,8,8a-tetrahidro-pirrol(1,2-a)pirazina-1(2h),4(3h)-dionas
NZ212051A (en) * 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JP2801491B2 (ja) * 1993-01-26 1998-09-21 敦 沼田 エピポリチオジオキソピペラジン誘導体およびその製造法
KR19990082168A (ko) * 1996-12-02 1999-11-25 에가시라 구니오 글리오톡신 유도체 및 이를 함유하는 항암제
US7202279B1 (en) * 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
US6906060B2 (en) * 2002-06-06 2005-06-14 Novo Nordisk A/S Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines
EP1664050B1 (en) * 2003-09-03 2015-12-09 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and pharmaceutical compositions containing them
US7253168B2 (en) * 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
ITMI20042477A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Uso di antibiotici a strutura dichetoditiopiperazinica per la preparazione di composizioni farmaceutiche antiangiogeniche
CA2596480A1 (en) * 2005-02-04 2006-08-10 Wisconsin Alumni Research Foundation Compounds and methods for modulating communication and virulence in quorum sensing bacteria
TW200800204A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Bicyclic piperazines as metabotropic glutatmate receptor antagonists
RU2318818C1 (ru) * 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
EP2088205A1 (en) * 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
WO2010075282A1 (en) * 2008-12-22 2010-07-01 University Of Washington Molecular inhibitors of the wnt/beta-catenin pathway
CN103189063B (zh) * 2010-11-01 2016-10-19 宾夕法尼亚州研究基金会 治疗组合物和方法
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
CN105229013B (zh) * 2013-05-24 2018-09-14 梨花女子大学校产学协力团 桥二硫双氧代哌嗪化合物或它的衍生物，及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1409085A (en) * 1971-11-22 1975-10-08 Licentia Gmbh Method and apparatus for data transmission
WO1997048706A1 (en) * 1996-06-18 1997-12-24 Warner-Lambert Company Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors
WO2008112014A1 (en) * 2006-10-05 2008-09-18 Mayo Foundation For Medical Education And Research Methods and compositions for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANFI, L. et al., "A convergent synthesis of enantiopure bicyclic scaffolds through multicomponent Ugi reaction", Tetrahedron, 2008, Vol. 64, No. 22, pages 1114-1134. *
GUENOUN, F. et al., "Pyrrolidinopiperazinedione as Chiral Auxiliary and its Use in Asymmetric Mannich Synthesis", Tetrahedron Letters, 1997, Vol. 38, No. 9, pages 1563-1566. *
OCCELLI, E. et al., "Substances with central nervous system activity. Derivatives of octahydro-1,4-dihydroxypyrrolo(1,2-a)pyrazine-6-carboxylic acids", Il Farmaco, 1984, Vol. 39, No. 8, pages 718-738. *

Also Published As

Publication number Publication date
CN104870452B (zh) 2018-04-13
JP2020125342A (ja) 2020-08-20
US9527868B2 (en) 2016-12-27
EP2909214B1 (en) 2020-07-22
JP2016500691A (ja) 2016-01-14
US20170037058A1 (en) 2017-02-09
JP2019070010A (ja) 2019-05-09
EP2909214A4 (en) 2016-04-20
CN108440571A (zh) 2018-08-24
US10246471B2 (en) 2019-04-02
US9856273B2 (en) 2018-01-02
EP2909214A1 (en) 2015-08-26
US20180155367A1 (en) 2018-06-07
JP6465803B2 (ja) 2019-02-06
CA2900335C (en) 2021-10-26
CN108440571B (zh) 2022-11-04
HK1214259A1 (en) 2016-07-22
CA2900335A1 (en) 2014-05-01
US20150291622A1 (en) 2015-10-15
AU2013334707A1 (en) 2015-05-07
WO2014066435A1 (en) 2014-05-01
CN104870452A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
AU2013334707B2 (en) ETP derivatives
EP3350181B1 (en) Her3 ligands and uses thereof
EP3395345A1 (en) Antitumor effect potentiator comprising pyrrolopyrimidine compound
EP3426637B1 (en) Compounds and methods for modulating bruton's tyrosine kinase
WO2017044889A1 (en) Lrh-1 modulators
AU2017358901A1 (en) Compounds and methods for modulating interleukin-2-inducible T-cell kinase
TR201905647T4 (tr) Cdk inhibitörleri olarak pirazolo[1,5-a]pirimidin-5,7-diamin bileşikleri ve onların terapötik kullanımı.
EP3632443B1 (en) Anti-tumor effect potentiator using a biphenyl compound
US20190119284A1 (en) ErbB Inhibitors and Uses Thereof
WO2016130581A2 (en) Combination cancer therapy
WO2017040693A1 (en) Broad spectrum antiviral compounds and uses thereof
US11584760B2 (en) Dithio ETP derivatives
HK1214259B (en) Etp derivatives
WO2018237190A1 (en) Pyridopyrazine compounds and uses thereof
HK1262897B (en) Compounds and methods for modulating bruton's tyrosine kinase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)